Clinical Trials Directory

Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C

The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in treatment-naive patients.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : Peginterferon alfa-2a
  • drug : nitazoxanide
  • drug : Ribavirin
  • drug : Placebo

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Chronic hepatitis C genotype 1.

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Shawna Thunen
Not Recruiting

Footer Links: